Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2010 - 2026)
Protalix BioTherapeutics' quarterly Total Non-Current Liabilities came in at $7.7 million in Q1 2026, up 76.96% year-on-year from $4.4 million in Q1 2025, and up 1.59% quarter-over-quarter from $7.6 million in Q4 2025.
Protalix BioTherapeutics has reported Total Non-Current Liabilities for 17 years, with the latest figure at $7.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 76.96% year-over-year to $7.7 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (up 76.96% YoY), and the FY2025 full-year result was $7.6 million, up 65.71% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $7.7 million, up from $7.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $40.5 million in Q1 2022, with the low at $4.4 million in Q1 2025.
- Average Total Non-Current Liabilities over 5 years is $15.9 million, with a median of $7.4 million recorded in 2025.
- Year-over-year, Total Non-Current Liabilities soared 445.93% in 2022 and tumbled 84.69% in 2024.
- Tracing PLX's Total Non-Current Liabilities over 5 years: stood at $34.0 million in 2022, then sank by 84.31% to $5.3 million in 2023, then declined by 14.06% to $4.6 million in 2024, then soared by 65.71% to $7.6 million in 2025, then rose by 1.59% to $7.7 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $7.7 million (Q1 2026), $7.6 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 7.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.72 Mn |
| Dec 31, 2025 | 7.60 Mn |
| Sep 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | 4.49 Mn |
| Mar 31, 2025 | 4.36 Mn |
| Dec 31, 2024 | 4.59 Mn |
| Sep 30, 2024 | 4.91 Mn |
| Jun 30, 2024 | 4.99 Mn |
| Mar 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | 5.34 Mn |
| Sep 30, 2023 | 5.96 Mn |
| Jun 30, 2023 | 26.31 Mn |
| Mar 31, 2023 | 34.04 Mn |
| Dec 31, 2022 | 34.00 Mn |
| Sep 30, 2022 | 33.92 Mn |
| Jun 30, 2022 | 39.57 Mn |
| Mar 31, 2022 | 40.55 Mn |
| Dec 31, 2021 | 46.53 Mn |
| Sep 30, 2021 | 40.51 Mn |
| Jun 30, 2021 | 8.12 Mn |
| Mar 31, 2021 | 7.43 Mn |
| Dec 31, 2020 | 8.50 Mn |
| Sep 30, 2020 | 61.73 Mn |
| Jun 30, 2020 | 64.06 Mn |
| Mar 31, 2020 | 66.13 Mn |
| Dec 31, 2019 | 75.54 Mn |
| Sep 30, 2019 | 91.26 Mn |
| Jun 30, 2019 | 96.73 Mn |
| Mar 31, 2019 | 93.86 Mn |
| Dec 31, 2018 | 88.66 Mn |
| Sep 30, 2018 | 89.35 Mn |
| Jun 30, 2018 | 75.97 Mn |
| Mar 31, 2018 | 76.09 Mn |
| Dec 31, 2017 | 78.92 Mn |
| Sep 30, 2017 | 60.54 Mn |
| Jun 30, 2017 | 60.55 Mn |
| Mar 31, 2017 | 120.03 Mn |
| Dec 31, 2016 | 25.99 Mn |
| Sep 30, 2016 | 75.24 Mn |
| Jun 30, 2016 | 75.38 Mn |
| Mar 31, 2016 | 75.38 Mn |
| Dec 31, 2015 | 75.15 Mn |
| Dec 31, 2014 | 69.60 Mn |
| Mar 31, 2014 | 110.21 Mn |
| Dec 31, 2013 | 113.58 Mn |
| Sep 30, 2013 | 112.64 Mn |
| Jun 30, 2013 | 47.66 Mn |
| Mar 31, 2013 | 51.82 Mn |
| Dec 31, 2012 | 56.33 Mn |
| Sep 30, 2012 | 52.17 Mn |
| Jun 30, 2012 | 55.11 Mn |
| Mar 31, 2012 | 57.20 Mn |
| Dec 31, 2011 | 59.19 Mn |
| Sep 30, 2011 | 59.87 Mn |
| Jun 30, 2011 | 60.31 Mn |
| Dec 31, 2010 | 57.15 Mn |